Table 4. Stage I/II tumours characterised by low (<2) or high (>2) FOXO3 expression.
| Baseline and tumour characteristics | Low FOXO3 | High FOXO3 | P-value |
|---|---|---|---|
| Age, years at diagnosis (mean+s.d.) |
74.8 (11.6) |
73.1 (10.6) |
0.598a |
| Gender (m : f) absolute numbers |
13 : 3 |
35 : 15 |
0.379b |
|
Tumour site |
|
|
0.272b |
| Caecum | 0 | 6 | |
| Ascending colon | 2 | 5 | |
| Transverse colon | 2 | 8 | |
| Descending colon/sigmoid colon | 3 | 17 | |
| Rectosigmoid colon | 2 | 2 | |
| Rectum | 7 | 10 | |
| Synchronous tumour | — | 1 | |
| Stoma |
— |
1 |
|
|
Surgical setting |
|
|
0.955b |
| Elective | 11 | 34 | |
| Emergency |
5 |
16 |
|
|
Histopathological data |
|
|
|
| Maximum tumour diameter (mm)
Mean (s.d.) |
45(20.3) |
47.5(21.8) |
0.688a |
|
T stage |
|
|
0.489b |
| T2 | 0 | 4 | |
| T3 | 11 | 30 | |
| T4 |
5 |
16 |
|
|
AJCC stage, 5th edition |
|
|
1.000c |
| Stage I | 0 | 3 | |
| Stage II |
16 |
47 |
|
| Extramural vascular invasion |
1 |
6 |
0.671c |
| Tumour perforation |
3 |
5 |
0.390c |
|
Adjuvant therapy |
|
|
|
| Neoadjuvant chemotherapy | 3 | 3 | 0.148c |
| Neoadjuvant radiotherapy | 5 | 3 | 0.017c |
| Adjuvant chemotherapy | 5 | 8 | 0.276c |
| Adjuvant radiotherapy |
1 |
4 |
1.000c |
| Recurrence |
14/16 |
19/50 |
|
| Mean DFS, months (s.d.) |
28.2(6.3) |
64.2(5.7) |
0.0001d |
| Mortality |
10/16 |
16/50 |
0.011d |
| Mean postoperative survival, months (s.d.) | 47.0(8.6) | 73.8(4.3) |
Abbreviations: DFS=disease-free survival; FOXO3=Forkhead/winged-helix-box-class-O3.
a
Independent t-test.
b
χ2-test.
c
Fisher's exact test.
d
Log-rank (Mantle–Cox's) test.